[
  {
    "ts": null,
    "headline": "Family Heart Foundation® Launches New Initiative to Increase Understanding and Screening for High Lipoprotein(a), the Most Common Genetic Risk Factor for Premature Cardiovascular Disease",
    "summary": "FERNANDINA BEACH, Fla., November 04, 2025--The Family Heart Foundation, the leading research, education and advocacy organization focused on genetic dyslipidemias, has launched the Lp(a) AW(a)RETM initiative to engage key U.S. healthcare stakeholders in advancing awareness, screening and diagnosis of high Lipoprotein(a) – also known as Lp(a). It is estimated that approximately 20% of the U.S. population has a genetic mutation for high Lp(a), yet only 1% in the general population, and 2% with est",
    "url": "https://finnhub.io/api/news?id=3f04c6b530fbe4e1350ffc2c917ae2f0c10e93bd038be5de8b40e5005e209fcb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762261200,
      "headline": "Family Heart Foundation® Launches New Initiative to Increase Understanding and Screening for High Lipoprotein(a), the Most Common Genetic Risk Factor for Premature Cardiovascular Disease",
      "id": 137312006,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "FERNANDINA BEACH, Fla., November 04, 2025--The Family Heart Foundation, the leading research, education and advocacy organization focused on genetic dyslipidemias, has launched the Lp(a) AW(a)RETM initiative to engage key U.S. healthcare stakeholders in advancing awareness, screening and diagnosis of high Lipoprotein(a) – also known as Lp(a). It is estimated that approximately 20% of the U.S. population has a genetic mutation for high Lp(a), yet only 1% in the general population, and 2% with est",
      "url": "https://finnhub.io/api/news?id=3f04c6b530fbe4e1350ffc2c917ae2f0c10e93bd038be5de8b40e5005e209fcb"
    }
  },
  {
    "ts": null,
    "headline": "Is Eli Lilly a Millionaire Maker?",
    "summary": "Eli Lilly has a leading position in a hot new drug category, but there's one notable problem to consider.",
    "url": "https://finnhub.io/api/news?id=cb321b4d84a7a5e9fce510c60e82a0e19a76dd7c050be7b0b2aafdeb947db7f7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762260300,
      "headline": "Is Eli Lilly a Millionaire Maker?",
      "id": 137312007,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly has a leading position in a hot new drug category, but there's one notable problem to consider.",
      "url": "https://finnhub.io/api/news?id=cb321b4d84a7a5e9fce510c60e82a0e19a76dd7c050be7b0b2aafdeb947db7f7"
    }
  },
  {
    "ts": null,
    "headline": "Here’s What Weighed on Eli Lilly and Company’s (LLY) Performance",
    "summary": "Baron Funds, an investment management company, released its “Baron Health Care Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund rose 5.39% (Institutional Shares) in the quarter, compared to a 5.05% gain for the Russell 3000 Health Care Index (benchmark) and an 8.18% gain for the Russell 3000 […]",
    "url": "https://finnhub.io/api/news?id=786237bc3f1be84a84eac2a8da9064df9e96b321e975f75b38b1491a4ceeae60",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762258694,
      "headline": "Here’s What Weighed on Eli Lilly and Company’s (LLY) Performance",
      "id": 137312008,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Baron Funds, an investment management company, released its “Baron Health Care Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund rose 5.39% (Institutional Shares) in the quarter, compared to a 5.05% gain for the Russell 3000 Health Care Index (benchmark) and an 8.18% gain for the Russell 3000 […]",
      "url": "https://finnhub.io/api/news?id=786237bc3f1be84a84eac2a8da9064df9e96b321e975f75b38b1491a4ceeae60"
    }
  },
  {
    "ts": null,
    "headline": "Anavex Life Sciences: Inching Closer To Binary Regulatory Outcome In The EU",
    "summary": "Anavex (AVXL) awaits a key EU ruling on its Alzheimerâs drug. Learn about trial challenges, approval risks, and why a Sell rating is advised.",
    "url": "https://finnhub.io/api/news?id=9b14383517a596c19d1c826771b161eb68042b8d9a20c85a762da0da49c4c4f1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762256639,
      "headline": "Anavex Life Sciences: Inching Closer To Binary Regulatory Outcome In The EU",
      "id": 137315657,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1383032509/image_1383032509.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Anavex (AVXL) awaits a key EU ruling on its Alzheimerâs drug. Learn about trial challenges, approval risks, and why a Sell rating is advised.",
      "url": "https://finnhub.io/api/news?id=9b14383517a596c19d1c826771b161eb68042b8d9a20c85a762da0da49c4c4f1"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly to invest $3bn in new Dutch manufacturing facility",
    "summary": "Among the medicines to be produced at the site will be orforglipron, the company’s oral small-molecule GLP-1 receptor agonist.",
    "url": "https://finnhub.io/api/news?id=fa1061ddec0cd1d1a029207bf79d74497f182ecef5f6da91a68648058fd47827",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762249661,
      "headline": "Eli Lilly to invest $3bn in new Dutch manufacturing facility",
      "id": 137312009,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Among the medicines to be produced at the site will be orforglipron, the company’s oral small-molecule GLP-1 receptor agonist.",
      "url": "https://finnhub.io/api/news?id=fa1061ddec0cd1d1a029207bf79d74497f182ecef5f6da91a68648058fd47827"
    }
  },
  {
    "ts": null,
    "headline": "Are Wall Street Analysts Predicting Eli Lilly Stock Will Climb or Sink?",
    "summary": "While the pharma giant Eli Lilly has lagged behind the broader market over the past year, it has outpaced the health care space, and analysts remain strongly bullish on the stock’s prospects.",
    "url": "https://finnhub.io/api/news?id=68850442bc9a61a01f0ba0fea2ecf05be7fe7eb3b4d09866331cda0aec2cffc5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762237321,
      "headline": "Are Wall Street Analysts Predicting Eli Lilly Stock Will Climb or Sink?",
      "id": 137312010,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "While the pharma giant Eli Lilly has lagged behind the broader market over the past year, it has outpaced the health care space, and analysts remain strongly bullish on the stock’s prospects.",
      "url": "https://finnhub.io/api/news?id=68850442bc9a61a01f0ba0fea2ecf05be7fe7eb3b4d09866331cda0aec2cffc5"
    }
  },
  {
    "ts": null,
    "headline": "At The Halfway Mark, S&P 500 Earnings Defy Headwinds As Tech And Health Care Deliver Strong Q3",
    "summary": "Q3 earnings growth continues to improve. With 64% of constituents reporting thus far, S&P 500 EPS growth for the quarter accelerated to 10.7%. This marks the second peak week of Q3 earnings.",
    "url": "https://finnhub.io/api/news?id=1e6a1f18d4ed032290e41221e4d3240752f97cff7a11be60e9f86aa75e21494c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762230600,
      "headline": "At The Halfway Mark, S&P 500 Earnings Defy Headwinds As Tech And Health Care Deliver Strong Q3",
      "id": 137310695,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2221411629/image_2221411629.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Q3 earnings growth continues to improve. With 64% of constituents reporting thus far, S&P 500 EPS growth for the quarter accelerated to 10.7%. This marks the second peak week of Q3 earnings.",
      "url": "https://finnhub.io/api/news?id=1e6a1f18d4ed032290e41221e4d3240752f97cff7a11be60e9f86aa75e21494c"
    }
  }
]